Australia’s TGA Decision: OTC CBD and the Medical Cannabis Revolution Down Under

From Strict Prohibition to 1.5 Million Prescriptions

Published February 1, 2023 — By Ann Karim, Senior Cannabis Editor

How the TGA Built One of the World’s Fastest Medical Cannabis Expansions

Australia’s Therapeutic Goods Administration (TGA) moved with unusual speed once the federal government decided to enable medical cannabis access in 2016. The TGA established two primary access pathways: the Special Access Scheme Category B (SAS-B), which allows any registered medical practitioner to apply for a specific patient, and the Authorised Prescriber scheme, which lets doctors become pre-approved to prescribe cannabis to entire classes of patients. Initially, both pathways were bureaucratically demanding, and prescription numbers grew slowly. The pivotal change came between 2019 and 2021, when the TGA simplified the SAS-B application process dramatically — reducing it from a multi-page document to a brief online form. Prescriptions surged immediately. By 2023, more than 1.5 million approvals had been issued, covering conditions from chronic pain and insomnia to anxiety and chemotherapy-related nausea. Australia now stands as a leading example of how regulatory design can drive rapid medical cannabis adoption without waiting for full recreational legalization. The market’s trajectory — from nearly zero to A$600 million in seven years — draws comparison to the growth curves seen in Canada’s post-legalization expansion.

“Australia has gone from one of the strictest cannabis countries to one of the most accessible medical markets in the world in under a decade.” — Cannabis industry analyst, 2023

OTC CBD: What the 2021 Scheduling Change Actually Means

In February 2021, the TGA reclassified low-dose cannabidiol (CBD) from Schedule 4 (prescription only) to Schedule 3 (pharmacist-only, no prescription required), making Australia one of only a handful of countries to allow OTC CBD sales. The change applied specifically to products containing no more than 150mg of CBD per recommended daily dose, with THC below 1% and CBN below 0.3%. In practice, this means consumers can walk into a pharmacy and purchase CBD without seeing a doctor — a significant shift in accessibility. The real-world rollout was slower than advocates hoped: pharmaceutical-grade Schedule 3 CBD products require TGA registration, and few products had cleared that bar by late 2023. Nevertheless, the regulatory door is open, and the pipeline of TGA-registered CBD consumer products was growing steadily. For higher-dose CBD or any THC-containing products, a prescription remains mandatory. Compare this approach to the UK, where CBD is available as a food supplement but medical cannabis requires specialist prescribing, or Germany, where the pharmacy-based medical system has been running since 2017. The global cannabis laws database tracks OTC CBD availability across all markets.

The ACT Experiment and What It Reveals

While federal recreational cannabis remains illegal across Australia, the Australian Capital Territory (ACT — Canberra and surrounding region) decriminalized personal possession of up to 50 grams and home growing of up to two plants in January 2020. The ACT experiment exposed a peculiar legal inconsistency: residents could possess cannabis legally under territory law but had no legal means of obtaining it, since purchase and supply remained federal offences. Despite this limitation, the ACT decriminalization demonstrated that policy change was politically achievable in Australia and that fears of social harm from decriminalization were not borne out by evidence. National polling consistently shows majority Australian support for recreational legalization — levels that parallel the trajectory seen in the US before state-by-state reform began accelerating. For travelers visiting Australia and wondering about cannabis access, consult our detailed Australia cannabis guide before making any assumptions based on the ACT rules, which do not apply elsewhere in the country.

What Australia’s Model Means for Global Medical Cannabis

Australia’s trajectory from strict prohibition to 1.5 million prescriptions in seven years offers a blueprint for countries considering medical cannabis legalization without full recreational reform. The TGA model — rigorous pharmaceutical standards, streamlined prescriber access, phased expansion of OTC availability — has produced a large, well-regulated market that generates tax revenue, creates jobs in cultivation and processing, and serves genuine patient needs. The A$600 million market figure is projected to grow significantly as more conditions are recognized, more products gain TGA registration, and the OTC CBD pipeline matures. For context, Australia’s success is mirrored across the 40-plus countries that now allow medical cannabis, from France to South Africa. The global case for medical-first regulatory approaches grows stronger with each year of data from markets like Australia, which prove that cautious, evidence-based reform can deliver substantial benefits without the political friction of immediate full legalization. Use our drug test calculator to understand detection windows for any cannabis product, medical or recreational.